A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours
Year: 2005
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: N. Steele, L. Vidal, J. Plumb, G. Attard, A. Rasmussen, P. Buhl-Jensen, R. Brown, S. Blagden, J. Evans, J. de Bono
Institution: Beatson West of Scotland Cancer Centre
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1849651317